Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postmarketing double-blind trial of milnacipran vs paroxetine for depression
jRCT1080220706Phase 4
- Sponsor
- Asahi Kasei Corporation
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of milnacipran in major depressive disorder (MDD) (2 arms), sponsored by Asahi Kasei Corporation.
02
Drugs
milnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT1080220706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080220706.